Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2022 May 31;10(5):e004699corr1. doi: 10.1136/jitc-2022-004699corr1

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

PMCID: PMC9157334  PMID: 35640932

Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J ImmunoTher Cancer 2022;10:e004699. doi: 10.1136/jitc-2022-004699.

This article has been corrected since it was first published online. In the ‘Case-report’ section, the dosage for intravenous abatacept in combination with oral ruxolitinib has been corrected to ‘15 mg two times daily’.


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES